-
Ocular Therapeutix NASDAQ:OCUL Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
Location: 24 Crosby Dr, Massachusetts, 01730-1402, US | Website: www.ocutx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.268B
Cash
459.7M
Avg Qtr Burn
-22.22M
Short % of Float
10.66%
Insider Ownership
1.06%
Institutional Own.
92.95%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DEXTENZA® (dexamethasone ophthalmic insert) Details Eye disease , Allergic conjunctivitis | Approved Quarterly sales | |
ReSure® Sealant Details Intraoperative management of clear corneal incision | Approved Quarterly sales | |
DEXTENZA® (dexamethasone ophthalmic insert) Details Inflammation and pain following ophthalmic surgery | Approved Quarterly sales | |
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Wet age-related macular degeneration , Eye disease | Phase 3 Data readout | |
OTX-CSI (cyclosporine intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
OTX-DED (dexamethasone intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
PAXTRAVA™ (OTX-TIC) (travoprost implant) Details Ocular hypertension, Primary open angle glaucoma | Phase 2 Update | |
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Diabetic retinopathy , Eye disease | Phase 1 Data readout |